Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL: 8,432 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
8,432
Total FAERS Reports
131 (1.6%)
Deaths Reported
647
Hospitalizations
8,432
As Primary/Secondary Suspect
33
Life-Threatening
27
Disabilities

Active Ingredient: COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE ·

First Report: 1993 · Latest Report: 20250115

What Are the Most Common COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL Side Effects?

#1 Most Reported
Bone density decreased
4,529 reports (53.7%)
#2 Most Reported
Renal injury
3,298 reports (39.1%)
#3 Most Reported
Skeletal injury
3,015 reports (35.8%)

All COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Bone density decreased 4,529 53.7% 48 221
Renal injury 3,298 39.1% 41 145
Skeletal injury 3,015 35.8% 41 138
Chronic kidney disease 2,468 29.3% 63 260
Tooth loss 2,440 28.9% 29 112
Bone loss 2,114 25.1% 20 102
Osteonecrosis 2,081 24.7% 22 113
Renal failure 2,033 24.1% 66 276
Tooth injury 1,967 23.3% 21 82
Multiple fractures 1,942 23.0% 24 122
Pain 1,827 21.7% 23 191
Emotional distress 1,806 21.4% 23 186
Osteoporosis 1,720 20.4% 15 113
Anxiety 1,672 19.8% 21 180
Anhedonia 1,631 19.3% 20 174
Osteopenia 1,070 12.7% 7 59
Economic problem 679 8.1% 14 86
Acute kidney injury 575 6.8% 27 203
Blood creatinine increased 531 6.3% 3 60
Renal impairment 472 5.6% 4 52

Who Reports COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL Side Effects? Age & Gender Data

Gender: 25.3% female, 74.7% male. Average age: 46.2 years. Most reports from: US. View detailed demographics →

Is COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL Getting Safer? Reports by Year

YearReportsDeathsHosp.
2000 4 1 0
2001 8 1 1
2002 15 0 0
2003 19 0 2
2004 33 1 3
2005 70 1 7
2006 79 0 9
2007 106 5 11
2008 150 3 16
2009 196 3 11
2010 257 4 19
2011 218 6 15
2012 341 2 36
2013 435 7 36
2014 631 12 79
2015 789 13 81
2016 806 16 66
2017 724 11 69
2018 664 10 44
2019 594 9 32
2020 233 3 10
2021 86 1 3
2022 40 0 1
2023 19 0 0
2024 5 0 0
2025 1 0 0

View full timeline →

What Is COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL Used For?

IndicationReports
Hiv infection 6,874
Product used for unknown indication 995
Acquired immunodeficiency syndrome 446
Hepatitis b 28
Prophylaxis against hiv infection 20
Hiv test positive 17
Antiretroviral therapy 10
Maternal exposure timing unspecified 9

COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL vs Alternatives: Which Is Safer?

COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL vs COBIMETINIB COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL vs COCAETHYLENE COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL vs COCAINE COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL vs COCOA BUTTER\PHENYLEPHRINE COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL vs COD LIVER OIL COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL vs CODEINE COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL vs CODEINE\GUAIFENESIN COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL vs CODEINE\IBUPROFEN COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL vs CODEINE\PROMETHAZINE COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL vs COLCHICINE

Official FDA Label for COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL

Official prescribing information from the FDA-approved drug label.